

**Adult CIRB – Early Phase Emphasis  
Meeting Agenda**

**Tuesday, March 6, 2018  
10:00 am – 12:20 pm (Eastern)**

---

**I. Initial Review**

**10096**, A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE) (Protocol Version Date 01/23/18)

---

**II. Amendment Review**

**9876**, Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer (Protocol Version Date 01/17/18)

---

**III. Continuing Review**

**9846**, Patient-Derived Models Tissue Procurement Protocol For The National Cancer Institute (NCI) (Protocol Version Date 01/02/18)

---

**IV. Continuing Review**

**9944**, Phase 2 Study of VX-970 (NSC# 780162) in Combination with gemcitabine versus gemcitabine alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer (Protocol Version Date 10/10/17)

---

**V. Continuing Review**

**10050**, A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer harboring KRAS G12R Mutation (Protocol Version Date 10/02/17)

---

**VI. Continuing Review**

**10067**, A randomized phase 2 trial of cediranib and olaparib compared to bevacizumab in patients with recurrent glioblastoma who have not received prior VEGF therapy (Protocol Version Date 09/28/17)

---

**VII. Continuing Review**

**A091304**, A Phase I /Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma (Protocol Version Date 10/26/17)